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ABSTRACT 
Pharmacovigilance outlined by the globe Health Organization (WHO) because the science and series of activities about the 
detection, evaluation, understanding rejection of adverse impact or Associate in Nursing different drug connected problem’ and a 
clinical test could be an analysis study in human volunteers to answer specific health queries. Fastidiously conducted clinical trials 
square measure quickest and safest thanks to realizing treatment that employment in individuals and thanks to improving health.  
Play a crucial role in guaranteeing that patient to be provided the safe drug. The Pharmacovigilance has been recognizing to play a 
crucial role in the rational use of the drug by providing data concerning the adverse impact possess by drug normally population. The 
information of drug Adverse Drug Reaction (ADRs) are often increased by numerous suggests that such information studies, 
intensive observation, spontaneous reportage and different new method at dictatorial and scientific level square measure being 
developed with the intention of step-up Pharmacovigilance. As a result of assessment strategies are not entirely void of individual 
judgments, integrator reliableness is often low. In conclusions, there's still no methodology universally accepted for casualty 
assessment of ADRs. 
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1. INTRODUCTION 
According to the world Health Organization, 
“Pharmacovigilance is defined as the science and 
activities relating to the detection, assessment, 
understanding and prevention of adverse effect or any 
other possible drug-related drawback, particular, long 
term and short term adverse effects of medicines” 1. The 
history routes of the word “Pharmacovigilance” are: 
Pharmakon (Greek word of ‘drug’) and vigilare (Latin 
word for ‘to keep watch’) 2. 
Pharmacovigilance is not new to Asian nation and has 
infect been going on from 1998 
3
.When Asian nations 
decided to join the Uppsala centre for adverse event 
monitoring. Spontaneous reporting of adverse drug 
reaction and adverse events is an important tool for 
gathering the safety data for early detection. it is widely 
accepted that a drug has to go through various phases of 
trial to establish its safety and efficacy before it is 
marketed commercially. However, the clinical trials 
offer various limitations, like; strict criteria of inclusion 
and exclusion make it to be used in a very selective 
group of patients; special population groups like kids, 
pregnant lady, and maturity population are not studied 
during the trials; and other factor causing drug reactions 
such as genetic factors, environmental factors, and drug-
drug interactions may not have been studied during the 
clinical trials 
4
. 
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These adverse drug reaction (ADRs) not only increase 
the suffering of patients but also increase morbidity and 
mortality in conjunction with a financial burden on 
society. the overall incidence of ADRs in hospitalized 
patients is estimated to be 6.7% (0.1-0.85%)
5
. data 
indicates that in patients World Health Organization 
experience ADRs death rates area unit 19.18% higher 
and the length of hospital stay is 8.25% higher. The 
Total medical cost for patient with ADRs unit increased 
by average of 19.86% 
6
. 
2. METHOD OF CAUSALITY ASSESSMENT 
 Many researchers developed numerous ways of relation 
assessment of ADRs by mistreatment totally different 
criteria like written record relationship between the 
administration of the drug and also the incidence of the 
ADR, screening for non drug connected causes, 
confirmation of the reaction by in vivo or vitro tests, and 
former data on similar events attributed to the suspect 
drug or to its therapeutic category, etc. to outline ADRs 
in several categories 
7
. However as a result of there 
aren't any outlined diagnostic criteria or classes, inter-
rater and intra-rater variability may be large 
8
. Currently, 
there's no universally accepted ways of accessing 
relation of ADRs 
[9]
. We tend to describe here 3 broad 
classes of varied ways of relation assessment: 
professional judgement/global contemplation, 
algorithms and probabilistic ways (Bayesian 
approaches) 
9
. 
 
3. HISTORY OF PHARMACOVIGILANCE IN ASIAN NATION 
Table 1: The sequential Pharmacovigilance developments with special reference to India 
Year Developments 
1747 Very first known clinical trials by James Lind, proving the usefulness of lemon juice in preventing scurvy. 
1937 Death of more than 100 children due to toxicity of sulfanilamide. 
1950 Apalstic anemia reported due to Chloramphenicol toxicity. 
1961 Worldwide tragedy due to thalidomide toxicity 
1963 16th World Health congregation recognize significant to rapid action on Adverse Drug Reactions (ADRs). 
1968 WHO research project for international drug monitoring on pilot scale. 
1996 Global standards level clinical trials initiated in India. 
1997 India attached with WHO Adverse Drug Reaction Monitoring Program. 
1998 Initiation of Pharmacovigilance in India. 
2002 67th National Pharmacovigilance Center established in India. 
2004-05 India launched National Pharmacovigilance Program. 
2005 Accomplishment of structured clinical trials in India. 
2009-10 Pharmacovigilance Program (Pv. PI) started. 
 
Pharmacovigilance in Asian nation started from 1986. A 
proper Adverse Drug Reaction (ADR) watching system 
was initiated with twelve regional centers, every 
covering a population of fifty million. However, no 
noteworthy growth was created. Later in 1997, Bharat 
joined the globe Health Organization (WHO) and 
Adverse Drug Reaction (ADR) scrutinized program 
primarily based at 2 urban centers, Kingdom of Sweden 
however got fail. Hence when 2005 UN agency 
supported and World Bank fund National 
Pharmacovigilance Programme (NPPV) of Bharat was 
created operational 
2,10,11,12
. The sequential 
Pharmacovigilance developments shown in below table 
no. 1 
1,13,14
. 
4. AIM OF PHARMACOVIGILANCE 
Improvement of patient care and safety in respect to use 
of medicines with medical and paramedical 
interventions remains to be a crucial parameter. The 
main objectives of Pharmacovigilance involve exhibiting 
the effectuality of medicine by observation their adverse 
impact profile for several years from the research lab to 
the pharmacy; trailing any forceful impact of drug rising 
public health and safety respect to the utilization of 
medicines; encouraging the safe, rational and efficient 
use of drugs; promoting understanding, educations and 
clinical coaching in Pharmacovigilance; and effective 
communications to the generic public 
15
. 
5. METHODS UTILIZED IN PHARMACO-
VIGILANCE 
The activities undertaken in the name of 
Pharmacovigilance can be roughly divided into three 
groups: regulatory, industry, and academia. Regulatory 
Pharmacovigilance is driven by the aim to provide drugs 
with a positive benefit- harm profile to the public. Some 
of the problems related to regulatory post-marketing 
surveillance will be discussed in this context, followed 
by a description of the methods used to detect new 
ADRs and a discussion of the pros and cons of each 
method 
16
. 
 Dangaumou’s French method 17 
 Kramer et al. method 18 
 Naranjo et al. methodology (Naranjo scale) 19 
 Balanced assessment method 20 
 Ciba-Geigy method 21 
 Loupi et al. method 22 
 Roussel Uclaf casuality assessment method 23 
 Australian method 24 
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6. ADVERSE DRUG REACTION (ADRs) 
An adverse drug (ADRs) is outline as AN fortuitous and 
harmful to a health product that causes at the doses 
sometimes or tested for the diagnosing, hindrance or 
treatment of a malady or the alteration of AN organic 
function 
25,26,27
 Though , it's tough to acknowledge the 
actuating agent connected with the adverse drug reaction 
(ADRs) encountered contain quite ingredients 
28
. The 
magnitude f risk must be thought-about together with 
magnitude of expected medical specialty advantages 
decide whether or to use a specific drug in an 
exceedingly given patient 
29
. Adverse drug (ADRs) are 
classified in two ways- 
 Foreseeable (Type-A) Reaction 
 Unpredictable (Type-B) Reaction 
Predictable (Type-A) Reaction: These square measure 
supported pharmacologic properties of the medicine like 
increased however quantitatively response to the drug 
that embody aspect effects, Gyanogenic effects and 
consequences of drug withdrawal 
28,31
. 
Unpredictable (Type-B) Reaction: These square 
measure supported peculiarities of patient and not on 
drug’s acknowledged actions; embody allergic reaction 
and specialty. These are less common, usually non dose 
connected, typically a lot of serious and need withdrawal 
of drug. an inventory of some suspected and 
acknowledged medicine related to adverse effect 
28,30,31
. 
The known Drug and its adverse effect shown in below 
table no. 2 
32
. 
 
Table 2: known Drug and its adverse effect. 
Drug Adverse Drug Reactions (ADRs) 
Thalidomide Phocomelia, Multiple defects 
Methotraxate Multiple defects, Foetal death 
Androgen Virilization, limb, esophageal, cardiac defects 
Progestins Virilization of female foetus 
Stilboestrol Vaginal carcinoma in teenage female offspring 
Tetracyclines Discolored or deformed teeth, retarded bone growth 
Warfarin nose, eye and hand defects, growth retardation 
Phenytoin Various malformations 
Lithium Foetal goiter, cardiac and other abnormalities 
Aspirin/ Indomethacin Premature closer of ductus arteriosus 
 
7. SIGNAL DETECTION AND EVALUATION STEPs:  
The evaluation steps for safety and prevention of ADR are shows in figure no. 1. (Reproduced with permission from 
the Report of CIOMS Working Group VIII  © 29[CIOMS-2010]. 
 
Figure 1: Signal detection and evaluation steps (reproduced with permission from the Report of CIOMS Working 
Group VIII 
33
 © CIOMS 
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8. CLINICAL TRIAL 
A clinical trial could be an analysis study that tests a 
replacement medical treatment or a replacement manner 
of mistreatment Associate in Nursing existing treatment 
to ascertain if it'll be higher thanks to stop and screen for 
diagnose or treat disease 
34.
 Wide selection of dose of the 
study drug is given to Associate in Nursingimals 
subjects or to an in-vitro substrate so as to get 
preliminary effectuality, toxicity and pharmacokinetic 
information 
35.
 The phase of clinical trial study was 
shown in figure no. 2. 
 
 
Figure 2: Phase of Clinical Trial 
Before pharmaceutical firms begin clinical test on a drug 
they conduct in depth pre-clinical studies 
36
. 
Pre-Clinical Studies 
Pre-clinical studies involve in vitro (i.e. tube or 
laboratory) studies and trial or animal population. Wide 
travel dose of the study in drug area unit given so as to 
get preliminary effectualness, toxicity and 
pharmacokinetic data and to help pharmaceutical firms 
decide whether or not it's worthy to travel ahead with 
more testing. 
Clinical Studies 
Phase-0 
Phase zero may be a recent designation for exploratory, 
first-in-human trial conducted in accordance with U.S. 
food and Drug administration (FDA) 2006 steerage on 
exploratory. Distinctive options of part zero trials 
embrace the administration of single sub-therapeutics 
doses of the study drug to a little range of subjects (10-
15) to collect preliminary information on the agent’s 
pharmacological medicine (how to body processes the 
drug) and Pharmacodynamics (how the drug add the 
body). 
Phase-I 
Phase I path area unit 1st stage of testing in human 
subject. Ordinarily a little (20-80) cluster of healthy 
volunteers are going to be elite. This part includes trails 
designed to assess the security (Pharmacovigilance) 
tolerability, pharmacological medicine and 
Pharmacodynamics of a drug. 
There are unit totally different styles of clinical trial 
trials. 
 SAD: Single Ascending Dose studies area unit 
those within which tiny cluster of subjects’ area unit 
given one dose of the drug whereas they're 
ascertained and tested for a amount of your time. 
 MAD: Multiple Ascending Dose studies area unit 
conducted to raise perceive the pharmacological 
medicine of multiple dose of drug. 
Phase-II 
Once the initial safety of the study drug has been 
confirmed in clinical trial trials, clinical trial trials area 
unit performed on giant cluster (20-300) and area unit 
designed to assess however well the drug work in 
addition on continue clinical trial safety assessment in a 
very larger cluster of volunteers and patients. clinical 
trial studies area unit generally divided into clinical trial 
A and clinical trial B. clinical trial A is specifically style 
to access dosing necessities ( what proportion drug 
ought to be given), wherever as clinical trial B is 
specifically designed to check effectualness ( however 
well the drug work the prescribed dose (s)). Some trials 
mix clinical trial and clinical trial, and take a look at 
each effectualness and toxicity. 
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Phase-III 
Phase III studies irregular controlled multi-center trials 
on giant patients cluster (300-3,000 or additional relying 
upon the disease/ medical condition studied) and area 
unit geared toward being the definitive assessment of 
however effective the drug is compared with current 
‘gold standard’ treatment. 
Phase-IV 
Phase IV trial is additionally called Post promoting 
police work Trial. Phase IV trials involves the security 
police work (Pharmacovigilance) and current technical 
support of a drug once it receive permission to sold.  
Table 3: Phases of Clinical Trial 
Phase Group 
0 10-15 
1 22-80 
1A Single Ascending Dose (SAD). 
1B Multiple Ascending Dose (MAD) 
2 20-300 
3 300-3000 
4 Post Marketing Surveillance Trial. 
 
The security police work is intended to observe any rare 
or semi permanent adverse result over a far larger 
patient population and longer period than was potential 
throughout the harmful result discovered by phase IV 
trials might end in a drug being not sold , or restricted to 
bound uses. Recent example involves Baycol (branch 
names Bycol and lipobay) trogelitazone (Rezulin and 
Vioxx-vioxx) 
35
. The segment of phase IV was shown in 
figure no. 3. 
CONCLUSION 
In conclusion there is still no method universally 
accepted for casuality assessment of ADRs. 
Pharmacovigliance study of the science and series of 
activities relating to the detection, evaluation, 
understanding and avoidance of Adverse Effect or any 
other drug related problem. The knowledge of drugs 
Adverse Drug Reaction (ADRs) can be augmented by 
various mean such database studies, intensive 
monitoring, spontaneous reporting. 
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